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Abstract: The thrombotic microangiopathy (TMA) score based on the development and morphological
characteristics of schistocytes is a rapid, simple biomarker that is easily obtained from the complete
blood cell count by an automated blood cell analyzer. We aimed to determine whether the TMA score
is associated with 30-day mortality of patients with early-stage septic shock. This observational cohort
study was retrospectively conducted based on a prospective emergency department (ED) registry
(June 2015–December 2016). We analyzed the TMA score at ED admission and 24 h later. The primary
endpoint was all-cause mortality within 30 days of ED admission. A total of 221 patients were included.
Increased TMA scores at time 0 (odds ratio (OR), 1.972; 95% confidence interval (CI), 1.253–3.106;
p = 0.003) and at time 24 (OR, 1.863; 95% CI, 1.863–3.066; p = 0.014) were strong predictors of 30-day
mortality. Increased predictability of 30-day mortality was closely associated with TMA scores ≥2 at
time 0 (OR, 4.035; 95% CI, 1.651–9.863; p = 0.002) and ≥3 at time 24 (OR, 5.639; 95% CI, 2.190–14.519;
p < 0.001). Increased TMA scores significantly predicted 30-day mortality for patients with severe
sepsis and septic shock and can be helpful when determining the initial treatment strategies without
additional costs or effort.
Keywords: sepsis; thrombotic microangiopathy score; mortality; predictor
1. Introduction
Sepsis is defined as life-threatening acute dysfunction of the organs due to a dysregulated response
to infection [1–3]. Although the in-hospital mortality rate has declined, it is still high (17.1%–18.0%) [2,4].
Since there are no completely effective pharmacological treatments for sepsis, early recognition, proper
management, and immediate treatment with appropriate antibiotics are important and should be
implemented to reduce the burden of subsequent disease [4]. To improve proper recognition and
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early management of sepsis, physicians should consider emergency departments (EDs) as key targets
because the majority of sepsis cases are present there [4].
Although the Acute Physiological and Chronic Health Evaluation (APACHE) II score and the
Sequential Organ Failure Assessment (SOFA) score have been commonly used for critically ill patients
because of their ability to reflect disease severity and represent organ dysfunction, respectively, their
rapid measurement is complicated [5].
The application of new biomarkers that quickly and easily predict the development of severe
complications and mortality in sepsis may improve the prognosis of patients by allowing early
aggressive treatment and innovative preventive and therapeutic options [6–8]. Since the thrombotic
microangiopathy (TMA) score is a more rapid and simple biomarker that is easily, simultaneously,
and automatically obtained from the complete blood cell (CBC) count by an automated blood cell
analyzer, we used this score to screen patients with severe sepsis or septic shock [5]. Systemic
endothelial injury develops in critically ill patients due to transplantation, autoimmune disease,
cancer, cardiopulmonary bypass, and exposure to infection, radiation, and medications [5,9]. TMA is
characterized by fragmented erythrocytes (schistocytes), thrombocytopenia, and higher levels of lactate
dehydrogenase [10]. When diagnosing TMA, an important criterion is the presence of ≥1% schistocytes
on a peripheral blood smear [10]. Moreover, the development of schistocytes in the blood reflects the
possibility of thrombocytopenia-associated multiple organ failure (TAMOF) [9].
The TMA score was developed to screen for TAMOF in critically ill patients; TAMOF is determined
based on the development and morphological characteristics of schistocytes [9]. However, schistocytes
are occasionally produced by severe hemolysis in turbulent areas of the microcirculation partially
occluded by platelet aggregations [11,12]. Schistocytes can be characterized by microcytic hyperchromic
red blood cells (RBCs), increased red cell distribution width (RDW), and increased hemoglobin
distribution width (HDW). The TMA score can be used for early detection of TAMOF based on
RBC parameters and the volume/hemoglobin concentration (V/HC) determined by an automated
hematology analyzer [9].
Similar to classic TMA, such as thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic
syndrome (HUS), a systemic response to severe infection and sepsis can induce disseminated
intravascular coagulation (DIC). With DIC, the activated cascade of coagulation causes thrombi
formation due to excessive fibrin in the intravascular microcirculation [13]. The excessive fibrin
formation induces thrombocytopenia and clotting factor consumption. Mechanical damage of the
RBCs by excess fibrin strands also leads to the formation of schistocytes [13]. Considering this
information, we designed this study to examine the development and morphological changes of
schistocytes during severe and septic shock. To the best of our knowledge, no studies have focused on
the advantages of using only the TMA score to predict short-term mortality of patients with sepsis. We
hypothesized that the TMA score could be used to predict the severity of sepsis and eventual mortality
for patients with severe and septic shock.
Additionally, lactate levels have been used clinically as a reliable indicator of the severity and
outcome of sepsis or septic shock because they traditionally reflect tissue hypoxia and can be measured
within a short time after ED admission using point-of-care testing [14,15]. Therefore, we aimed to
determine whether the initial TMA score was significantly associated with 30-day mortality for patients
with early-stage septic shock and whether combining the initial lactate concentrations with the TMA
score improved the ability to predict unfavorable outcomes.
2. Experimental Section
2.1. Study Population
This observational cohort study was retrospectively conducted based on a prospective registry of
the ED of Severance Hospital, which is affiliated with Yonsei University College of Medicine and is a
tertiary-level referral hospital with a population of approximately 85,000 patients per year between
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June 2015 and December 2016. This study was reviewed and approved by the Institutional Review
Board (3-2017-0060) of the Yonsei University Health System. The requirement for written informed
consent from patients was waived 1) because of the use of the prospective early goal-directed therapy
(EGDT)/SEPSIS registry of the ED and 2) because this study retrospectively analyzed data based on
de-identified medical records of the subjects.
Since November 2007, the EGDT, which has been referred to as SEPSIS since June 2015 because
of the changes in the EGDT, has been implemented as a critical pathway (CP) program at our
institution as part of a quality improvement initiative [6]. To provide appropriate treatment for
sepsis, we designed a standard treatment with bundled management to reduce unnecessary delays
in the hospital by implementing rapid decision-making by specialists [6,16]. When a patient with
suspicious signs of infection arrives at the ED, emergency physicians identify whether that patient is a
candidate for this program as soon as possible by using predetermined guidelines based on systemic
inflammatory response syndrome (SIRS). We included patients who presented with two SIRS criteria
and one CP criterion (hypotension or high lactate value) as a result of infection at the time of ED
admission [6,16]. We classified patients with suspected infections admitted to the ED as presenting with
SIRS [6,16]. As a result of infection, we defined SIRS by the presence of two or more of the following
criteria [6,16]: Temperature <36 ◦C or >38 ◦C; heart rate >90 beats/min; respiratory rate >20 breaths/min
or PaCO2 <32 mmHg; and white blood cell (WBC) count >12,000 cells/µL or <4000 cells/µL or band
neutrophil count >10% [6,16]. Then, we assessed the patient’s eligibility for the CP program. Those
who presented with SIRS and had at least one of the following inclusion criterion at the time of ED
admission were finally included in the CP program: Systolic blood pressure <90 mmHg despite a 20-
to 30-mL/kg intravenous crystalloid fluid challenge or serum lactate level ≥4 mmol/L at the time of
ED admission [6,16]. The following cases were excluded or deactivated from the CP program: Age
younger than 18 years; pregnancy; acute cerebrovascular or coronary syndrome; active gastrointestinal
bleeding; contraindication to central venous catheter; trauma; necessity for immediate surgery; transfer
to another hospital within six hours after ED admission; and do not resuscitate status. We included
consecutive patients who were prospectively integrated in the CP program for sepsis treatment based
on predetermined protocols [6]. Additionally, we excluded patients with prosthetic valves, patients
who received a transplant, and patients undergoing chemotherapy.
2.2. Data Collection
The following demographic data were collected from the registry: Age; sex; body weight; medical
history, including hypertension, diabetes mellitus, cardiovascular disease, heart failure, chronic kidney
disease, cancer, and chronic liver disease; hemodynamic parameters; laboratory results, including CBC
count, routine chemistry, C-reactive protein (CRP), lactate, albumin, procalcitonin, and blood culture
results; in-hospital course, including time of antibiotics initiation; clinical outcomes; and follow-up
period. To evaluate the clinical severity of each patient’s case, the SOFA score was determined using
the worst values obtained during the initial 24 h of the ED admission.
2.3. Assessment of TMA Score
The TMA score ranges from 0 to 5 points, with 1 point given for each of the following:
RDW >15%, HDW >3.2%, percentage of microcytes ≥0.4% (percentage of microcytes indicates
the percentage of RBCs smaller than 60 fL), percentage of hyperchromic red cells ≥1.9% (percentage
of hyperchromic red cells indicates the percentage of RBCs with more than 41 g/dL of hemoglobin),
and platelet count <140 × 109/L [9]. All these RBC parameters were measured using an automated
blood cell analyzer (ADVIA 120, Siemens, Forchheim, Germany) [9]. The percentages of microcytes
and hyperchromic red cells were calculated using the V/HC cytogram [9]. The TMA score was
automatically calculated and reported [9]. To investigate the usefulness of TMA to predict the
development of short-term mortality, we analyzed the TMA scores at the time of ED admission and 24 h
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later. We collected venous blood of the subject in ethylenediaminetetraacetic-containing vacutainers
within 15 min after ED admission (time 0) and within 24 ± 6 h after admission (time 24).
2.4. Clinical Endpoints
The primary endpoint was the all-cause mortality within 30 days of ED admission.
2.5. Statistical Analysis
Demographic and clinical data are represented as medians and interquartile ranges (IQRs),
means and standard deviations, percentages, or frequencies, as appropriate. Continuous variables
were compared using the two-sample t-test or Mann-Whitney U-test, and categorical variables were
compared using the χ2 test or Fisher’s exact test. To identify the significance of the differences between
the groups over time, a linear two-factor mixed model was conducted using a repeated-measures
covariance pattern and unstructured covariance within patients. We used two fixed effects for this
model: The time effect (TMA at time 0 and time 24) and the diagnostic effect for the clinical endpoint
(development and non-development of 30-day mortality). Univariable analyses were performed to
identify the significance of the relationships among the demographic and clinical data. To highlight
the predictor of 30-day mortality, variables with p < 0.05 were selected from our univariable analysis
and the promising predictors of 30-day mortality during the early stage of sepsis were clarified using
multivariable logistic regression analysis with a stepwise approach. Consequently, the results are shown
for forward conditional stepwise selections of clinical markers with p < 0.05 for entry and p < 0.05 for
retention. We created receiver-operating characteristic (ROC) curves and determined the area under
the curve (AUC) to identify the ability of the TMA score to predict 30-day mortality. We performed
Youden’s method to verify the optimal cutoff of the delta neutrophil index for discriminating between
the development and non-development of 30-day mortality. These results are represented as odds ratios
(ORs) and 95% confidential intervals (CIs). After considering the development of 30-day mortality and
its AUC, we compared the diagnostic performances of the TMA score and each marker, including WBC,
CRP, lactate, and procalcitonin, on ED admission. Based on the optimal cutoff values of 2 for TMA on
ED admission and of 3 for TMA at time 24, Kaplan–Meier survival curves were created using 7-day
and 30-day mortality data, and the groups were compared using the log-rank test.
In addition, to increase the early predictability of 30-day mortality during the ED admission,
we analyzed the ROC curve of lactate on ED admission by combining the TMA score over time and
the lactate value on admission. Based on the optimal cutoff values of 2 for TMA on ED admission,
of 3 for TMA at time 24, and of 4 for lactate with regard to the sepsis guidelines, we classified three ED
admission groups and three time 24 groups. The ED admission groups were based on optimal cutoff
values of 2 for TMA and 4 for lactate: Group 1, lactate <4 and TMA <2; group 2, lactate ≥4 and TMA <2
or lactate <4 and TMA ≥2; and group 3, lactate ≥4 and TMA ≥2. The time 24 groups were based on
an optimal cutoff value of 3 for TMA and 4 for lactate: Group 1, lactate <4 and TMA <3; group 2,
lactate ≥4 and TMA <3 or lactate <4 and TMA ≥3; and group 3, lactate ≥4 and TMA ≥3. We identified
sensitivity and specificity according to groups. Sensitivity, specificity, positive predictive values, and
negative predictive values of the TMA score, lactate concentrations, and a combination of the TMA
score and lactate concentrations for predicting 30-day mortality were defined. Statistical analyses
were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC) and MedCalc Statistical Software
version 16.4.3 (MedCalc Software bvba, Ostend, Belgium), and p < 0.05 was considered significant.
3. Results
3.1. Study Population, Clinical Evaluation, and Treatment
Figure 1 shows the inclusion and clinical outcomes of subjects with septic shock registered in the
EGDT/SEPSIS program (Figure 1). A total of 204 patients were included in this study, and 31 patients
experienced 30-day mortality after ED admission (Table 1). The incidence of the all-cause 30-day
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mortality was 15.2%. Ninety-one of them were male (44.61%), and the mean age was 67 ± 15 years.
The mortality group (29.03%) showed higher rates of cardiovascular disease than did the survival
group (13.87%, p = 0.035). The SOFA score was significantly increased in patients who died within
30 days (10.39 ± 2.93), as compared with patients who survived (7.11 ± 2.53, p < 0.001). There were
significant differences for lactate, albumin, and total CO2 between the two groups (p of all <0.001).
TMA score at time 0 and 24 were significantly increased in patients who died as compared to patients
who survived (1.42 ± 1.02 and 1.69 ± 1.16 in the survival group versus 2.23 ± 1.15 and 2.82 ± 1.30
in the mortality group, p of all <0.001). Patients who experienced 30-day mortality had significantly
higher TMA scores than those who did not. Mean admission to antibiotics time was 3.64 h (SD 4.54),
and this was significantly shorter in patients who died within 30 days compared to those who did
not (2.70 ± 1.44 vs. 3.81 ± 4.88, p = 0.016). The linear mixed model revealed significant differences in
the TMA scores between patients grouped according to the development and non-development of
30-day mortality (group, p < 0.001; time, p < 0.001; and group × time, p = 0.007) after ED admission
(Figure 2A).
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SOFA score (points) 7.61 ± 2.84 7.11 ± 2.53 10.39 ± 2.93 <0.001 * 
Initial Vital Sign     
Systolic blood pressure (mmHg) 85.46 ± 24.03 86.73 ± 23.39 78.32 ± 26.61 0.073 
Diastolic blood pressure (mmHg) 52.93 ± 15.10 53.83 ± 15.2 47.90 ± 13.72 0.044 * 
Heart rate (bpm) 104.46 ± 24.72 104.10 ± 25.70 106.45 ± 18.55 0.545 
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Diabetes mellitus 66 (32.35) 52 (30.06) 14 (45.16) 0.098 
Cardiovascular disease 33 (16.18) 24 (13.87) 9 (29.03) 0.035 * 
Heart failure 7 (3.43) 6 (3.47) 1 (3.23) >0.999 
Chronic kidney disease 23 (11.27) 21 (12.14) 2 (6.45) 0.54 
Liver disease 23 (11.27) 19 (10.98) 4 (12.90) 0.759 
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Table 1. Clinical characteristics of patients stratified by 30-day mortality.
Variables
Total Survival Death p
N = 204 (100%) N = 173 (84.8%) = 31 (15.2%)
Age (years) 67 ± 15 66 ± 15 72 ± 11 0.016 *
Male sex (n (%)) 91 (44.61) 78 ( 5.09) 13 (41 94) 0.745
BMI (kg/m2) 21.47 ± 3.43 21.41 ± 3.36 21.82 ± 3.83 0.542
SOFA score (points) 7.61 ± 2.84 7.11 ± 2.53 10.39 ± 2.93 <0.001 *
Initial Vital Sign
Systolic blood pressure (mmHg) 85.46 ± 2 .03 86.73 ± 23.39 78.32 ± 26.61 0.073
Diastolic blood pressure ( mHg) 52.93 ± 15.10 53.83 ± 15.2 47.90 ± 13.72 0.044 *
Heart rate (bpm) 104.46 ± 24.72 104.10 ± 25.70 106.45 ± 18.55 0.545
Respiratory rate (bpm) 18.59 ± 3.72 18.57 ± 3.82 18.71 ± 3.19 0.844
Body temperature (◦C) 37.51 ± 3.03 37.83 ± 1.32 35.719 ± 6.94 0.102
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Table 1. Cont.
Variables
Total Survival Death p
N = 204 (100%) N = 173 (84.8%) N = 31 (15.2%)
Comorbidity (n (%))
Hypertension 121 (59.31) 102 (58.96) 19 (61.29) 0.808
Diabetes mellitus 66 (32.35) 52 (30.06) 14 (45.16) 0.098
Cardiovascular disease 33 (16.18) 24 (13.87) 9 (29.03) 0.035 *
Heart failure 7 (3.43) 6 (3.47) 1 (3.23) >0.999
Chronic kidney disease 23 (11.27) 21 (12.14) 2 (6.45) 0.54
Liver disease 23 (11.27) 19 (10.98) 4 (12.90) 0.759
Malignancy 52 (25.49) 43 (24.86) 9 (29.03) 0.623
Treatment
Admission to antibiotics time (hours) 3.64 ± 4.54 3.81 ± 4.88 2.70 ± 1.44 0.016 *
Admission to vasopressor time (hours) 2.63 ± 3.92 2.76 ± 4.20 1.92 ± 1.59 0.052
Antibiotics administration <3 h (n (%)) 135 (66.18) 111 (64.16) 24 (77.42) 0.151
Laboratory Data
White blood cell count (103/µL) 13.88 ± 9.25 14.16 ± 8.65 12.33 ± 12.15 0.429
Hematocrit (%) 35.88 ± 6.52 36.10 ± 6.04 34.62 ± 8.73 0.37
Platelet count (103/µL) 185 ± 106 188 ± 98 169 ± 144 0.486
Neutrophil count (103/µL) 12.40 ± 8.77 12.70 ± 8.20 10.72 ± 11.49 0.363
Prothrombin time (INR) 1.25 ± 0.39 1.23 ± 0.40 1.37 ± 0.34 0.069
Creatinine (mg/dL) 2.07 ± 1.65 1.99 ± 1.62 2.54 ± 1.78 0.088
C-reactive protein (mg/L) 160 ± 117 158 ± 116 175 ± 121 0.459
Procalcitonin (ng/mL) 28.60 ± 36.26 28.25 ± 36.71 30.67 ± 34.08 0.745
Albumin (g/dL) 3.14 ± 0.66 3.21 ± 0.61 2.73 ± 0.77 <0.001 *
Lactate (mmol/L) 3.53 ± 3.22 2.87 ± 2.23 7.14 ± 5.02 <0.001 *
Total CO2 (mmol/L) 17.45 ± 4.39 18.18 ± 3.86 13.23 ± 4.95 <0.001 *
Bacteremia (n (%)) 102 (50.00) 83 (47.98) 19 (61.29) 0.172
TMA score Time 0 (points) 1.55 ± 1.08 1.42 ± 1.02 2.23 ± 1.15 <0.001 *
TMA score Time 24 (points) 1.83 ± 1.23 1.69 ± 1.16 2.82 ± 1.30 <0.001 *
* p < 0.05; BMI, body mass index; SOFA, sequential organ failure assessment; TMA, thrombotic microangiopathy.
3.2. TMA Score as a Predictor of 30-Day Mortality for Sepsis
The ROC curve analysis of the prediction of 30-day mortality indicated that the AUCs regarding
the TMA score at time 0 and time 12 were 0.697 (IQR, 0.589–0.789; p < 0.001) and 0.738 (IQR, 0.6–0.853;
p < 0.001), respectively (Figure 2B,C). The univariable analysis showed significant differences in
the TMA scores at different time points for patients who did and did not develop 30-day mortality
(Supplementary Table S1). Further multivariable logistic regression analyses demonstrated that
increased TMA scores at time 0 (OR, 1.972; 95% CI, 1.253–3.106; p = 0.003) and time 24 (OR, 1.863;
95% CI, 1.863–3.066; p = 0.014) were strong predictors of 30-day mortality (Table 2). The optimal cut-off
values of the TMA scores at time 0 and time 24 were 2 (sensitivity, 77.4 (IQR, 62.7–92.1); specificity:
54.1 (IQR, 46.6–61.5)) and 3 (sensitivity: 63.6 (IQR, 43.5–83.7); specificity: 76.3 (IQR, 69.6–83.1)),
respectively (Figure 2B,C). The increased predictability of 30-day mortality in the present study was
closely associated with a TMA score ≥2 at time 0 (OR, 4.035; 95% CI: 1.651–9.863; p = 0.002) and a TMA
score ≥3 at time 24 (OR, 5.639; 95% CI: 2.190–14.519; p < 0.001; Figure 2B,C). Higher TMA scores at
admission and 24 h after admission were significantly associated with an increased risk of 30-day and
7-day mortality among patients with septic shock (Figure 3A,B and Supplementary Table S4).
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Figure 3. The thrombotic microangiopathy (TMA) score as predictor of 30-day mortality. Higher TMA
scores at admission (A) and 24 h (B) after admission were significantly associated with an increased
risk of 30-day mortality a ong patients with septic shock.
3.3. Comparison of the TMA Score and Conventio l rkers as Predictors of Mortality for Patients
with Sepsis
Comparisons of the ROC curves perfor t ict the development of 30-day mortality
showed that the AUC for the TMA score at ED admission was sign ficantly superio to CRP. The AUC
for the TMA score at time 24 was significantly superior to those f r CRP and proc lcitonin. Moreover,
the TMA scores at ED admi sion an time 24 were not significan ly i ferior to SOFA sc res within 24 h
and lactate at ED admission (Figure 4 and Supplem nt ry Table S2).
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Figure 4. Comparison of the area under the curve (AUC) for the thrombotic microangiopathy (TMA)
score when predicting the 30-day mortality (A). The AUC showed discriminative abilities for risk
stratification of 30-day mortality. Statistical information is shown in Supplementary Table S2. The AUC
of TMA at 24 h was statistically superior to the C-reactive protein and procalcitonin concentration, and
it was not inferior to the Sequential Organ Failure Assessment (SOFA) score, and lactate concentration
according to the early goal-directed therapy (EGDT)/SEPSIS critical pathway
Table 2. Multivariable logistic regression analysis for predictors of 30-day mortality.
Variable
Enter Method
OR (95% CI) p OR (95% CI) p
SOFA score (per 1 point) 1.237 (1.012–1.513) 0.038 * 1.184(0.949–1.476) 0.134
History of cardiovascular disease 2.730 (0.818–9.108) 0.102 2.831(0.687–11.671) 0.15
Albumin (g/dL) 0.515(0.225–1.179) 0.116 0.484(0.198–1.182) 0.111
Total CO2 (per 1 mmol/L) 0.898(0.767–1.052) 0.184 0.918(0.762–1.106) 0.368
Lactate (per 1 mmol/L) 1.247(1.039–1.497) 0.018 * 1.298(1.047–1.609) 0.018 *
TMA score Time 0 (per 1 point) 1.928(1.187–3.130) 0.008 *
TMA score Time 24 (per 1 point) 1.683 (0.996–2.844) 0.052
Variable
Stepwise Selection
OR (95% CI) p OR (95% CI) p
SOFA score (per 1 point) 1.264 (1.062–1.505) 0.008 *
History of cardiovascular disease
Albumin (g/dL) 0.410 (0.178–0.945) 0.036 *
Total CO2 (per 1 mmol/L)
Lactate (per 1 mmol/L) 1.338 (1.156–1.548) <0.001 * 1.430 (1.207–1.693) <0.001 *
TMA score Time 0 (per 1 point) 1.972 (1.253–3.106) 0.003 *
TMA score Time 24 (per 1 point) 1.863 (1.132–3.066) 0.014 *
* p < 0.05; OR, odds ratio; CI, confidence interval; SOFA, sequential organ failure assessment; TMA,
thrombotic microangiopathy.
3.4. Prognostic Value of the TMA Score in Combination with Lactate on ED Admission
To improve the predictability of clinical outcomes early after ED admission, we demonstrated
how predictability was improved when the TMA score was added to the lactate level on ED admission.
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The AUC of the addition of the TMA score at time 0 or time 24 to the lactate level (0.857 (p = 0.034)
and 0.892 (p = 0.018)) on ED admission was significantly improved compared to the AUC of the lactate
level alone (0.8; IQR, 0.703–0.878; Figure 5 and Supplementary Table S3). We obtained sensitivity and
specificity using a combination of the optimal cutoff of the TMA score and lactate level. For those in the
ED admission groups based on optimal cut-off values of 2 for TMA and 4 for lactate, the sensitivity and
specificity for patients with lactate≥4 and TMA <2 or lactate <4 and TMA≥2 were 96.8 (IQR, 90.6–100.0)
and 41.2 (IQR, 33.8–48.6). Sensitivity and specificity for those with lactate ≥4 and TMA ≥2 were 45.2
(IQR, 27.6–62.7) and 88.8 (IQR, 84.1–93.6). For those in the time 24 groups based on optimal cut-off
values of 3 for TMA and 4 for lactate, the sensitivity and specificity for lactate ≥4 and TMA <3 or
lactate <4 and TMA ≥3 were 90.9 (IQR, 78.6–100.0) and 61.3 (IQR, 53.5–69.1). Sensitivity and specificity
for those with lactate ≥4 and TMA ≥3 were 40.9 (IQR, 20.4–61.5) and 92.7 (IQR, 88.5–96.8; Table 3).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 9 of 13 
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Table 3. Sensitivity, specificity, positive predictive value, and negative predictive value of the TMA
score, lactate, and a combination of lactate with the TMA score for predicting the 30-day mortality of
patients with septic shock.
Variable Sensitivity(%)
Specificity
(%) PPV (%) NPV (%) OR (95% CI)
TMA score 0 ≥ 2 77.4(62.7–92.1)
54.1
(46.6–61.5)
2 .3
(15.1–31.5)
93.0
(88.0–98.0)
4.035
(1.651–9.863)
TMA score 24 ≥ 3 63.6(43.5–83.7)
76.3
(69.6–83.1)
28.0
(15.6–40.4)
93.5
(89.2–97.9)
5.639
(2.190–14.519)
Lactate ≥ 4.0 64.5(47.7–81.4)
7 .4
(69.0–81.9)
2.3
(20.6–43.9)
92.1
(87.7–96.6)
5.584
(2.474–12.603)
TMA score 0 ≥ 2 and
Lactate ≥ 4.0
45.2
(27.6–62.7)
88.8
(84.1–93.6)
42.4
(25.6–59.3)
89.9
(85.3–94.4)
6.545
(2.788–15.362)
TMA score 24 ≥ 3 and
Lactate ≥ 4.0
40.9
(20.4–61.5)
92.7
(88.5–96.8)
45.0
(23.2–66.8)
91.4
(87.0–95.9)
8.748
(3.066–24.960)
TMA score 0 ≥ 2 or
Lactate ≥ 4.0
96.8
(90.6–100.0)
41.2
(33.8–48.6)
23.1
(15.8–30.3)
98.6
(95.9–100.0)
20.998
(2.798–157.588)
TMA score 24 ≥ 3 or
Lactate ≥ 4.0
90.9
(78.9–100.0)
61.3
(53.5–69.1)
25.6
(16–35.3)
97.9
(95.0–100.0)
15.862
(3.574–70.398)
AUC, area under curve; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive
predictive value; TMA, thrombotic microangiopathy.
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4. Discussion
In the present study, sepsis patients who died within 30 days after ED admission had significantly
higher TMA scores than did those who survived. The higher TMA scores at time 0 and time 24 were
significant predictors of 30-day mortality. Sepsis is a clinically complex condition that is characterized
by a systemic inflammatory response accompanying an infection [6,17]. Although early recognition
and treatment of sepsis has significantly decreased its mortality rate over the years, it remains high.
The pathophysiology of sepsis is very complex and poorly understood. Among various
mechanisms of sepsis-induced organ failure, sepsis is significantly associated with the activation
of the coagulation cascade that sometimes leads to DIC, which is its more severe clinical form [18].
Although the classic forms of TMA are HUS and TTP, several different forms such as DIC, atypical
hemolytic uremic syndrome, scleroderma renal crisis, malignant hypertension, antiphospholipid
antibody syndrome, and drug toxicities are considered other conditions of TMA [19]. The schistocyte
count is not a clue to the initial diagnosis of DIC in sepsis and is not completely specific to TMA.
Nevertheless, the International Council for Standardization in Hematology (ICSH) recommended that
the presence of >1% schistocytes on a peripheral blood smear without other moderate RBC changes
is an important criterion for the diagnosis of TMA; furthermore, Lesesve et al. suggested that the
presence of >1% schistocytes was frequently related to various circumstances in which the increased
schistocyte count indicated severe infection, pregnancy, and leukemia [10,20,21]. Most patients with
DIC after septicemia had schistocytes, although only approximately 0.5% were seen. Visudhiphan et al.
proposed that there was no difference in schistocyte counts of sepsis patients with and without DIC [22].
Lesesve et al. suggested that it is difficult to differentiate schistocytes that originated from DIC because
sepsis itself and renal impairment caused by sepsis can create schistocytes in patients with sepsis [21].
Considering the pathogenesis of severe sepsis and septic shock and the significant association
between sepsis and DIC, increased schistocyte development may be significantly associated with
the severity of sepsis and septic shock. Moreover, Bateman et al. proposed that the mechanisms
of erythrocytes during sepsis are changed by the increased rigidity and decreased deformability of
RBCs [23]. These changes in erythrocytes are clinically relevant for sepsis patients [23]. First, decreased
erythrocyte deformability develops early, within 24 h of admission of critically ill patients, and does
not recover in septic patients. This RBC deformability progressively decreases over the next two
to eight days in patients with infections and is significantly associated with organ dysfunction and
the outcomes of sepsis patients [23,24]. Therefore, RBC injury in sepsis can lead to microvascular
dysregulation and mechanical damage and has a significant role in the formation of schistocytes [23].
In the present study, the TMA score ranged from 0 to 5 points and was used based on simple
changes similar to the morphological characteristics of schistocytes to evaluate whether increased TMA
scores can predict the severity of sepsis and the development of 30-day mortality for patients with septic
shock after ED admission [9]. The optimal cutoff values of TMA scores at time 0 and time 24 were 2
and 3. We demonstrated that TMA scores ≥2 at time 0 and ≥3 at time 24 increased the predictability of
30-day mortality for patients with sepsis. The score can be very meaningful during the early stage of
sepsis because we assessed the changes in schistocytes rather than the absolute schistocyte counts.
The TMA score is automatically calculated and reported by an automated hematology analyzer when
performing a CBC count, and no additional costs or laboratory tests are necessary [5,9]. It is a simple
and rapidly measurable marker [5]; therefore, our results demonstrated that the TMA scores for those
with sepsis could be a useful ancillary marker. Several studies revealed the usefulness of the automated
counting of RBC fragments as a routine screening tool, good agreement with microscopy, and other
advantages [10,20].
There was no significant increase in the predictability of 30-day mortality with the addition
of TMA scores to SOFA scores, but the addition of TMA scores to lactate levels on ED admission
could significantly increase the predictability of 30-day mortality. Similar to the TMA score, which
can be obtained simultaneously with CBC analysis results, lactate levels can be obtained soon after
ED admission using point-of-care testing. A high concentration of serum lactate was significantly
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associated with higher in-hospital mortality rates and 90-day mortality rates compared to isolated
refractory hypotension among septic patients [25,26]. Gotmaker et al. demonstrated that patients with
an isolated blood lactate level >4 mmol/L were at greater risk for mortality than those with isolated
refractory hypotension [26]. They also proposed that a lactate level >4 mmol/L should be considered
a key risk stratification tool even in the absence of refractory hypotension in patients with suspected or
proven infection after ED admission [26]. Based on the optimal cutoff TMA scores for ED admission
and time 24 and the critical value of lactate on ED admission, we designed a simple, intuitive, and
categorical predictor with good sensitivity and specificity. When the optimal cutoff values of TMA
scores at time 0 and time 24 were 2 and 3, sensitivity values were 77.4 (IQR, 62.7–92.1) and 63.6
(IQR, 43.5–83.7) and specificity values were 54.1 (IQR, 46.6–61.5) and 76.3 (IQR, 69.6–83.1). If only
one of the cutoff values for the TMA score or lactate level is exceeded in patients with sepsis, then
the sensitivity of the prediction of 30-day mortality is significantly increased. If both cutoff values for
the TMA score and lactate level are exceeded, then the specificity is significantly increased. The TMA
score in the ED may be useful to predict 30-day mortality in patients with severe sepsis and septic
shock. Combining TMA score with lactate concentrations improves the predictive performance for
the prognosis and may contribute to rapid risk stratification of patients with severe sepsis and/or
septic shock.
The TMA score reflects the development of schistocytes and implies mechanical hemolysis by
partial occlusion of the microcirculation, and increased lactate values suggest deterioration of tissue
hypoxia caused by microcirculation dysfunction. Therefore, the TMA score is helpful when making
a clinical decision during the early stage of sepsis.
The present study had several limitations. Although this study included a prospective CP using
a predetermined standardized protocol, it was performed retrospectively using a cohort derived
from the CP of a single, tertiary, academic hospital. Therefore, the design of this study could have
caused a selection bias because it was difficult to control confounding factors. Since January 2019,
the EGDT/SEPSIS as a CP protocol was revised to new SEPSIS according to the third international
consensus definitions for sepsis and septic shock (Sepsis-3) [27]. However, because of the timing of the
study period, we did not include septic patients enrolled according to the new sepsis CP. We relied on
the explicit Sepsis-2 to identify and enroll sepsis and septic shock cases in the registry [28]. Further
prospective, multicenter trials are required to validate the usefulness of the TMA scores as a prognostic
marker for severe sepsis or septic shock as defined by their third international consensus definitions.
The TMA scores in the present study ranged from 0 to 5 points and were designed based on
the development of schistocytes and changes similar to morphological characteristics of schistocytes.
We could not directly compare the correlation between automatically measured TMA scores and the
schistocyte percent estimated by microscopically counting.
Finally, despite the use of a prospective registry as the CP, we could not measure ADAMTS-13
activity, which is known as an important factor in the pathophysiology of the classic form of TMA,
because it was not a mandatory biomarker. However, the objective of this study was to investigate the
severity of sepsis by detecting the development of schistocytes using automatic measurements.
5. Conclusions
We found that increased TMA scores predicted the 30-day mortality of patients with severe sepsis
and septic shock. Combining TMA score with initial lactate concentrations can improve the predictive
performance of short-term mortality. The TMA score is automatically measurable by an automated
hematology analyzer. It can be quickly measured without additional costs or effort; therefore, the TMA
score may be a promising tool for rapid risk stratification of patients with severe sepsis and/or septic
shock in need of intensive care and innovative therapies.
Supplementary Materials: The following are available at http://www.mdpi.com/2077-0383/8/6/808/s1. Table S1:
Univariate logistic regression analysis of predictors of 30-day mortality, Table S2: Comparing scoring systems and
biomarkers for the prediction of 30-day mortality using the area under the curve, Table S3: Comparison of the
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performance of the prediction of 30-day mortality with and without the TMA score by area under the receiver
operating characteristic curve, Table S4: The TMA score as a predictor of 7-day mortality.
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